.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Cantor Fitzgerald
Citi
QuintilesIMS
Baxter
Chinese Patent Office
Federal Trade Commission
Healthtrust
Cerilliant
Harvard Business School

Generated: November 18, 2017

DrugPatentWatch Database Preview

Teva Pharms Usa Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA PHARMS USA, and what generic alternatives to TEVA PHARMS USA drugs are available?

TEVA PHARMS USA has one hundred and forty-four approved drugs.

There are five US patents protecting TEVA PHARMS USA drugs on TEVA PHARMS USA drugs in the past three years. There are nineteen tentative approvals on TEVA PHARMS USA drugs.

There are fifty-five patent family members on TEVA PHARMS USA drugs in thirty-one countries and two hundred and ninety-four supplementary protection certificates in thirteen countries.

Summary for Teva Pharms Usa

International Patents:55
US Patents:5
Tradenames:124
Ingredients:122
NDAs:144
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa
GRANISETRON HYDROCHLORIDE
granisetron hydrochloride
INJECTABLE;INJECTION078392-001Dec 31, 2007APRXNoYes► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL200532-002Apr 24, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
CARBOPLATIN
carboplatin
INJECTABLE;IV (INFUSION)077139-002Sep 21, 2005APRXNoYes► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
ARIPIPRAZOLE
aripiprazole
TABLET;ORAL078607-002Apr 28, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014APRXYesYes► Subscribe► Subscribe ► Subscribe
Teva Pharms Usa
GRANISETRON HYDROCHLORIDE
granisetron hydrochloride
INJECTABLE;INJECTION077963-001Jan 3, 2008APRXNoYes► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
ATAZANAVIR SULFATE
atazanavir sulfate
CAPSULE;ORAL091673-002Apr 22, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
DEXMETHYLPHENIDATE HYDROCHLORIDE
dexmethylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL078908-002Nov 19, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
CEFTRIAXONE
ceftriaxone sodium
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS065227-003Mar 15, 2007DISCNNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE
amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL202491-003Nov 3, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Teva Pharms Usa

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622-001Dec 20, 1996► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622-001Dec 20, 1996► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622-001Dec 20, 1996► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-002Feb 12, 2002► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-002Feb 12, 2002► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-002Feb 12, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for TEVA PHARMS USA drugs

Drugname Dosage Strength Tradename Submissiondate
omeprazole
Delayed-release Tablets20 mg
OMEPRAZOLE
6/3/2015
glatiramer acetate
Injection40 mg/mL, 1 mL pre-filled syringe
COPAXONE
2/26/2014
glatiramer acetate
Injection40 mg/mL, 1 mL pre-filled syringe
COPAXONE
1/29/2014

International Patent Family for Teva Pharms Usa Drugs

Country Document Number Estimated Expiration
Spain2612001► Subscribe
CroatiaP20170056► Subscribe
Spain2424692► Subscribe
Serbia55607► Subscribe
Israel233468► Subscribe
Japan6038653► Subscribe
Eurasian Patent Organization201400394► Subscribe
SloveniaEP2949335► Subscribe
Portugal2949335► Subscribe
Eurasian Patent Organization201270292► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Teva Pharms Usa Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2015Austria► SubscribePRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720
C0012France► SubscribePRODUCT NAME: IMATINIB MESILATE; NAT. REGISTRATION NO/DATE: EU/1/01/198/001 20011107; FIRST REGISTRATION: LI - IKS 55 807 20010621
00172Netherlands► SubscribePRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN SIMVASTATINE; NAT. REGISTRATION NO/DATE: RVG 30927RVG 30928RVG 30929RVG 30930 2004221122; FIRST REGISTRATION: 58874.00.0058874.01.0058874.02.0058874.03.0058878.00.0058878.01.0058878.02.0058878.03.0058866.00.0058866.01.0058866.02.0058866.03.0058870.00.0058870.01.0058870.02.0058870.03.00 2004020402
C0037Belgium► SubscribePRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826
00357Netherlands► SubscribePRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZOUT, IN HET BIJZONDER HET MONOFOSFAAT, EN METFORMINE DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716
0801067/01Switzerland► SubscribePRODUCT NAME: SOLIFENACIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57203 12.05.2006
/2008Austria► SubscribePRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE ALS MONOPHOSPHAT, UND METFORMIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REGISTRATION: CH 58450 01-03 20080408
C0103Belgium► SubscribePRODUCT NAME: CALCII ATORVASTATINUM TRIHYDRICUM (=ATORVASTATINUM); NAT. REGISTRATION NO/DATE: 19 IS 95 F 3 19970922; FIRST REGISTRATION: GB PL/00018/0240 19961107
00677Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121
0625Netherlands► SubscribePRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Mallinckrodt
AstraZeneca
Chubb
Dow
Citi
US Army
McKesson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot